AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares were up 11.9% during trading on Friday . The company traded as high as $3.15 and last traded at $3.10. Approximately 3,615,965 shares were traded during mid-day trading, an increase of 150% from the average daily volume of 1,446,457 shares. The stock had previously closed at $2.77.

A number of research analysts recently commented on AVEO shares. Seaport Global Securities restated a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. BidaskClub lowered AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Zacks Investment Research lowered AVEO Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 6th. assumed coverage on AVEO Pharmaceuticals in a research note on Wednesday, November 15th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, B. Riley assumed coverage on AVEO Pharmaceuticals in a research note on Monday, November 13th. They issued a “buy” rating and a $5.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $4.05.

The firm has a market cap of $366.75, a P/E ratio of -4.37 and a beta of 1.14. The company has a current ratio of 2.33, a quick ratio of 2.33 and a debt-to-equity ratio of -0.32.

A number of large investors have recently added to or reduced their stakes in the stock. RA Capital Management LLC acquired a new stake in AVEO Pharmaceuticals in the second quarter valued at about $18,727,000. Vanguard Group Inc. boosted its stake in AVEO Pharmaceuticals by 48.6% in the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after buying an additional 1,162,232 shares in the last quarter. EAM Investors LLC acquired a new stake in AVEO Pharmaceuticals in the second quarter valued at about $1,979,000. Essex Investment Management Co. LLC acquired a new stake in AVEO Pharmaceuticals in the third quarter valued at about $550,000. Finally, OxFORD Asset Management LLP acquired a new stake in AVEO Pharmaceuticals in the third quarter valued at about $228,000. 50.91% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “AVEO Pharmaceuticals (AVEO) Trading Up 11.9%” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/01/12/aveo-pharmaceuticals-aveo-trading-up-11-9.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.